---
layout: default
title: Actaea Spicata Root Anagallis Arvensis Argemone Me
parent: 僅模型預測 (L5)
nav_order: 151
evidence_level: L5
indication_count: 0
---

# Actaea Spicata Root Anagallis Arvensis Argemone Me
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Preparation: Insufficient Data for Drug Repurposing Evaluation

## One-Sentence Summary

This candidate consists of 12 botanical, biological, and mineral homeopathic ingredients (including *Actaea spicata* root, *Hyoscyamus niger*, potassium dichromate, and roasted sea sponge), with no approved indications, no US market authorization, and no DrugBank ID on record.
The TxGNN model generated **no predicted indications** for this candidate, meaning no drug repurposing direction can currently be proposed.
Without a DrugBank identifier or structured pharmacological profile, the pipeline was unable to map this compound to the knowledge graph.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None documented |
| Predicted New Indication | No prediction generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only (no prediction available) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction was generated for this candidate. The following explains why repurposing analysis cannot proceed at this time.

This entry represents a complex multi-ingredient preparation composed of 12 components drawn from homeopathic pharmacopoeia, including plant extracts (*Actaea spicata*, *Anagallis arvensis*, *Argemone mexicana*, *Hyoscyamus niger*, *Senna leaf*), a biological agent (*Candida albicans*), an animal-derived venom (*Heloderma horridum* venom), mineral salts (potassium dichromate, potassium iodide, potassium nitrate, dibasic potassium phosphate), and a roasted marine organism (*Spongia officinalis* skeleton).

Individually, several components have known pharmacological activity at standard doses — for example, hyoscine alkaloids from *Hyoscyamus niger* are anticholinergic, sennosides from senna are laxative, and potassium iodide has established use in thyroid conditions. However, as a combined homeopathic formulation, the preparation lacks a unified mechanism of action (MOA), and no DrugBank entity could be mapped to the multi-ingredient string as a whole.

Because TxGNN's knowledge graph operates on single drug entities with DrugBank IDs and defined molecular targets, this preparation falls outside the scope of the current prediction pipeline. A meaningful repurposing evaluation would require decomposing the formulation and analyzing each pharmacologically active component independently.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this multi-ingredient preparation as a combined entity.

---

## Literature Evidence

Currently no related literature available for this multi-ingredient preparation as a combined entity.

---

## US Market Information

This preparation has no US NDA or market authorization on record. The TFDA query returned 0 results, confirming it is not currently marketed or licensed.

---

## Safety Considerations

Please refer to the package insert for safety information.

> Note: No safety data (warnings, contraindications, or drug-drug interactions) was retrievable for this preparation. Several individual components carry known safety concerns at pharmacological doses — for example, *Hyoscyamus niger* contains anticholinergic alkaloids, *Argemone mexicana* contains toxic isoquinoline alkaloids, and potassium dichromate is classified as a carcinogen and nephrotoxin. Any clinical use or investigation would require component-level toxicology review.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline was unable to generate any repurposing predictions because this multi-ingredient homeopathic preparation cannot be mapped to a single DrugBank entity or knowledge graph node. Without a structured pharmacological profile, the evidence base is insufficient to support a repurposing hypothesis.

**To proceed, the following is needed:**

- **DrugBank ID or structured entity mapping**: Determine whether any individual component (e.g., hyoscyamine from *Hyoscyamus niger*, sennosides from senna) should be analysed independently as a repurposing candidate
- **Regulatory clarification**: Confirm whether this preparation is intended as a homeopathic product (OTC, non-prescription) or as a drug requiring full regulatory dossier
- **MOA documentation**: For each pharmacologically active component, retrieve mechanism of action data from DrugBank or primary literature
- **Component-level TxGNN run**: Decompose the formulation and submit each active ingredient separately through the repurposing pipeline
- **Safety review**: Conduct component-level toxicology assessment, particularly for *Argemone mexicana* (argemone oil toxicity), potassium dichromate (Cr⁶⁺ carcinogenicity), and *Heloderma horridum* venom (exendin-class peptides)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

